Publication at Third Faculty of Medicine |
2021
Abstract
Arterial hypertension (AH) belongs to main risk factors of cardiovascular diseases which have a high mortality rate in adult population. Due to the low prevalence of AH in children, pharmacological therapy of hypertension does not belong to the routine practice of pediatricians.
Moreover, in children younger than 6 years, the etiology of high blood pressure (BP) is dominated by secondary hypertension whose treatment is reserved for specialized centres. The review article is focused on the long-term pharmacotherapy of primary hypertension in children older than 6 years.
The aim is to provide a basic orientation to current pharmacotherapy recommendations and highlight the potential benefits and risks of the medication.